Does anticholinergics drug burden relate to global neuro-disability outcome measures and length of hospital stay?

M Sakel, A Boukouvalas, R Buono, M Moten, F Mirza, W-Y Chan, I Maidment, J Cross, T O Smith, P K Myint, C Fox

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)


PRIMARY OBJECTIVE: To assess the relationship between disability, length of stay (LOS) and anticholinergic burden (ACB) with people following acquired brain or spinal cord injury.

RESEARCH DESIGN: A retrospective case note review assessed total rehabilitation unit admission.

METHODS AND PROCEDURES: Assessment of 52 consecutive patients with acquired brain/spinal injury and neuropathy in an in-patient neuro-rehabilitation unit of a UK university hospital. Data analysed included: Northwick Park Dependency Score (NPDS), Rehabilitation complexity Scale (RCS), Functional Independence Measure and Functional Assessment Measure FIM-FAM (UK version 2.2), LOS and ACB. Outcome was different in RCS, NPDS and FIM-FAM between admission and discharge.

MAIN OUTCOMES AND RESULTS: A positive change was reported in ACB results in a positive change in NPDS, with no significant effect on FIM-FAM, either Motor or Cognitive, or on the RCS. Change in ACB correlated to the length of hospital stay (regression correlation = -6.64; SE = 3.89). There was a significant harmful impact of increase in ACB score during hospital stay, from low to high ACB on NPDS (OR = 9.65; 95% CI = 1.36-68.64) and FIM-FAM Total scores (OR = 0.03; 95% CI = 0.002-0.35).

CONCLUSIONS: There was a statistically significant correlation of ACB and neuro-disability measures and LOS amongst this patient cohort.

Original languageEnglish
Pages (from-to)1426-1430
Number of pages5
JournalBrain Injury
Issue number12
Early online date5 Aug 2015
Publication statusPublished - 2015


  • anticholingeric
  • function
  • rehabilitation unit
  • length of stay
  • adverse effect
  • spinal cord
  • traumatic brain injury


Dive into the research topics of 'Does anticholinergics drug burden relate to global neuro-disability outcome measures and length of hospital stay?'. Together they form a unique fingerprint.

Cite this